Structure via PubChem · Public domain (PubChem)
olaparib
Sign in to saveAlso known as AZD-2281, AZD2281, Lynparza®, KU59436, 4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one, 1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine
Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 462264805
- Drug.image
- Olaparib.svg
- Drug.image_class
- skin-invert-image
- Drug.caption
- Above: molecular structure of olaparib Below: 3D representation of an olaparib molecule
- Drug.image2
- Olaparib 3D.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Lynparza, others
- Drug.MedlinePlus
- a614060
- Drug.DailyMedID
- Olaparib
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- XK01
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_UK
- POM
via Wikipedia infobox
Chemical data
- Formula
- C24H23FN4O3
- Molecular weight
- 434.5 g/mol
- IUPAC name
- 4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one
- SMILES
- C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F
- InChIKey
- FDLYAMZZIXQODN-UHFFFAOYSA-N
- XLogP
- 1.9
- Polar surface area
- 82.1 Ų
- H-bond donors
- 1
- H-bond acceptors
- 5
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2014
- Admin. routes
- oral
- Indications
- neoplasm, ovarian carcinoma, prostate adenocarcinoma, non-small cell lung carcinoma
via ChEMBL · EBI
Research
4,162 papers- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.The New England journal of medicine · 2017
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.The Lancet. Oncology · 2017
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.The New England journal of medicine · 2018
- Olaparib.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2018
- OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2019
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 434.175
- Has use
- medication
Show 6 more facts
- chemical formula
- C₂₄H₂₃FN₄O₃
- canonical SMILES
- C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F
- World Health Organisation international non-proprietary name
- olaparib
- subject has role
- PARP inhibitor
- Commons category
- Olaparib
- medical condition treated
- ovarian cancer
Sources (6)
via Wikidata · CC0
~9 min read
Encyclopedic overview
5 sectionsContents
- Medical uses
- Side effects
- Mechanism of action
- History
- References
Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.
In December 2014, olaparib was approved for use as a single agent by the European Medicines Agency (EMA) in the European Union and by the Food and Drug Administration (FDA) in the United States.
Excerpted from Wikipedia’s “olaparib” article, available under the CC BY-SA 4.0 licence.